Archive for the ‘oncology retractions’ Category
The authors of a letter replying to a comment in a urology journal have retracted their response because it contained inappropriate figures. At least, that’s the official story.
The original paper, “Effect of a Risk-stratified Grade of Nerve-sparing Technique on Early Return of Continence After Robot-assisted Laparoscopic Radical Prostatectomy,” came from a group at Weill Medical College of Cornell University led by Ashutosh Tewari. Published in July 2012 in European Urology, it purported to find that: Read the rest of this entry »
A former postdoc at MD Anderson Cancer Center faked the results of a mouse study of a Novartis compound designed to fight brain tumors, according to the Office of Research Integrity (ORI).
Jun Fu “admitted to knowingly and intentionally falsifying Figure 8a” in “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating Cells,” a paper published in Cancer Research on May 15, 2013:
A paper about a protein being used — unapproved by health agencies — to treat diseases including cancer and autism has been retracted.
The paper, “Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells,” appeared in the July 2013 issue of the Journal of Drug Design, Development and Therapy, a Dove Press title.
The paper, “GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in Breast Cancer,” came from a team composed of researchers at the Morehouse School of Medicine, Xavier University of Louisiana and the University of Miami School of Medicine. It purported to find that: Read the rest of this entry »